AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Patients with ulcerative colitis in remission who had a history of nonspecific arthritis, arthralgia, or another condition treatable with NSAID therapy did not have a greater relapse rate with the use of celecoxib for up to 14 days than with placebo, Dr. William J. Sandborn and his colleagues reported.
In a double-blind, pilot trial, 221 patients were randomized to receive oral celecoxib 200 mg or placebo twice daily for 14 days. Ulcerative colitis (UC) exacerbation occurred in 3 of 110 evaluated patients on celecoxib and in 4 of 107 on placebo (Clin. Gastroenterol. Hepatol. 2006;4:203-11). The study was supported by a research grant from Pfizer Inc.
In a second study, Dr. Ken Takeuchi and his colleagues studied patients with quiescent Crohn's disease or UC. First, they randomized 109 patients to 4 weeks of treatment with either acetaminophen or a conventional NSAID (naproxen, diclofenac, or indomethacin). Of patients taking NSAIDs, 17%-28% had a relapse; whereas no patients taking acetaminophen relapsed (Clin. Gastroenterol. Hepatol. 2006;4:196-202).
...
Source: HighBeam Research, COX-2 inhibitors in IBD patients.(Inflammatory Bowel Disease )(Drug...